Education
About Us
Working with TipRanks
Follow Us
Lipella Pharmaceuticals, Inc. (LIPO)
:LIPO
RESEARCH TOOLSreports
LIPO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $12.00
Previous CloseN/A
Volume96.41K
Average Volume (3M)50.47K
Market Cap
$3.66M
Enterprise Value$139.14M
Total Cash (Recent Filing)$4.23B
Total Debt (Recent Filing)$24.00M
Price to Earnings (P/E)―
Beta-0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.78
Shares Outstanding4,467,395
10 Day Avg. Volume103,608
30 Day Avg. Volume50,469
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)30.76
Price to Sales (P/S)0.00
P/FCF Ratio-78.54
Enterprise Value/Market Cap37.99
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$10.00Price Target Upside1119.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Lipella Pharmaceuticals, Inc. News
PremiumCompany Announcements
Lipella Pharmaceuticals Announces Nasdaq Delisting
PremiumCompany Announcements
Lipella Pharmaceuticals Faces Nasdaq Delisting
PremiumCompany Announcements
Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date
PremiumCompany Announcements
Lipella Pharmaceuticals Faces Nasdaq Compliance ChallengePremiumCompany Announcements
Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsLipella announced positive results from its P2a study of LP-310 in oral lichen planus (OLP), highlighting data from the first cohort which received the lowest treatment dose of 0.25mg.
Regulatory ApprovalFDA granted approval for an expanded access program (EAP) for LP-310, its oral rinse formulation of tacrolimus, for the treatment of oral lichen planus (OLP).
Stock PerformanceShares are up ~60% on the news.
Bears Say
Financial RequirementsThe company will likely need to raise additional capital to fund its ongoing programs.
Options Prices
Currently, No data available
---
Ownership Overview
29.72% Insiders
0.19% Mutual Funds
0.30% Other Institutional Investors
69.70% Public Companies and Individual Investors
LIPO FAQ
What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?
Lipella Pharmaceuticals, Inc. lowest stock price was $0.62 and its highest was $12.00 in the past 12 months.
What is Lipella Pharmaceuticals, Inc.’s market cap?
Lipella Pharmaceuticals, Inc.’s market cap is $3.66M.
When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?
Lipella Pharmaceuticals, Inc. released its earnings results on Mar 31, 2023. The company reported -$1.487 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.487.
Is Lipella Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Lipella Pharmaceuticals, Inc. pay dividends?
Lipella Pharmaceuticals, Inc. does not currently pay dividends.
What is Lipella Pharmaceuticals, Inc.’s EPS estimate?
Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipella Pharmaceuticals, Inc. have?
Lipella Pharmaceuticals, Inc. has 4,467,395 shares outstanding.
What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?
Lipella Pharmaceuticals, Inc. reported an EPS of -$1.487 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.622%.
Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LIPO
Company Description
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Technical Analysis
Palatin Technologies
―
MetaVia
―
Aptorum Group
―
TransCode Therapeutics
―
Conduit Pharmaceuticals
―